Graham I Harrison1, Karen Murray2, Roxanne Gore3, Penelope Lee4, Aravamuthan Sreedharan2, Paul Richardson3, Amanda J Hughes5, Martin Wiselka6, Will Gelson7, Esther Unitt8, Karen Ratcliff9, Annette Orton4, Kerry Trinder4, Charlotte Simpson9, Stephen D Ryder10, Sandra Oelbaum9, Graham R Foster11, Archie Christian12, Stuart Smith12, Brian J Thomson10, Rosy Reynolds13, Magdalena Harris14, Matthew Hickman13, William L Irving1. 1. NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK. 2. United Lincolnshire Hospitals Lincoln County Hospital, Lincoln, UK. 3. Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK. 4. Change Grow Live, Walsall, UK. 5. Walsall Healthcare NHS Trust, Walsall, UK. 6. University Hospitals of Leicester NHS Trust, Leicester, UK. 7. Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK. 8. University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. 9. Addaction, Clerkenwell, London, UK. 10. Nottingham University Hospitals NHS Trust, Nottingham, UK. 11. QueenMary University of London, London, UK. 12. The Hepatitis C Trust, London, UK. 13. Population Health Sciences, University of Bristol, Bristol, UK. 14. Department of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, London, UK.
Abstract
BACKGROUND AND AIMS: Previous studies have shown low rates of diagnosis and treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID). Our aims were to test the effect of a complex intervention [Hepatitis C Awareness Through to Treatment (HepCATT)] in drug and alcohol clinics-primarily, on engagement of HCV-positive PWID with therapy and, secondarily, on testing for HCV, referral to hepatology services and start of HCV treatment. DESIGN AND SETTING: A non-randomized pilot study in three specialist addiction clinics in England comparing an intervention year (starting between September 2015 and February 2016) with a baseline year (2014), together with three control clinics. PARTICIPANTS: Analysis included all attendees at the intervention and control specialist addiction clinics identified as PWID. INTERVENTION: The intervention comprised the placement of a half-time facilitator in each clinic for 12 months with the brief to increase diagnosis of HCV infection within clients at those services and the engagement of diagnosed individuals with an appropriate care pathway. The facilitator undertook various activities, which could include training of key workers, direct interaction with clients, streamlining and support for hepatology appointments and introduction of dried blood-spot testing. MEASUREMENTS: For each clinic and period, we obtained the total number of clients and, as relevant, their status as PWID, tested for HCV, known HCV-positive, engaged with HCV therapy or treated. FINDINGS: Compared with baseline, there was strong evidence that engagement with HCV therapy in the intervention year increased (P < 0.001) more in the HepCATT centres than controls, up + 31 percentage points [95% confidence interval (CI) = 19-43] versus -12 (CI = -31 to + 6) and odds ratio (OR) = 9.99 (CI = 4.42-22.6) versus 0.35 (CI = 0.08-1.56). HepCATT centres also had greater increases in HCV testing (OR = 3.06 versus 0.78, P < 0.001), referral to hepatology (OR = 9.60 versus 0.56, P < 0.001) and treatment initiation (OR = 9.5 versus 0.74, P < 0.001). CONCLUSIONS: Introducing a half-time facilitator into drug and alcohol clinics in England increased engagement of HCV-positive people who inject drugs with hepatitis C virus care pathways, with increased uptake also of testing, referral to hepatology and initiation of treatment.
BACKGROUND AND AIMS: Previous studies have shown low rates of diagnosis and treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID). Our aims were to test the effect of a complex intervention [Hepatitis C Awareness Through to Treatment (HepCATT)] in drug and alcohol clinics-primarily, on engagement of HCV-positive PWID with therapy and, secondarily, on testing for HCV, referral to hepatology services and start of HCV treatment. DESIGN AND SETTING: A non-randomized pilot study in three specialist addiction clinics in England comparing an intervention year (starting between September 2015 and February 2016) with a baseline year (2014), together with three control clinics. PARTICIPANTS: Analysis included all attendees at the intervention and control specialist addiction clinics identified as PWID. INTERVENTION: The intervention comprised the placement of a half-time facilitator in each clinic for 12 months with the brief to increase diagnosis of HCV infection within clients at those services and the engagement of diagnosed individuals with an appropriate care pathway. The facilitator undertook various activities, which could include training of key workers, direct interaction with clients, streamlining and support for hepatology appointments and introduction of dried blood-spot testing. MEASUREMENTS: For each clinic and period, we obtained the total number of clients and, as relevant, their status as PWID, tested for HCV, known HCV-positive, engaged with HCV therapy or treated. FINDINGS: Compared with baseline, there was strong evidence that engagement with HCV therapy in the intervention year increased (P < 0.001) more in the HepCATT centres than controls, up + 31 percentage points [95% confidence interval (CI) = 19-43] versus -12 (CI = -31 to + 6) and odds ratio (OR) = 9.99 (CI = 4.42-22.6) versus 0.35 (CI = 0.08-1.56). HepCATT centres also had greater increases in HCV testing (OR = 3.06 versus 0.78, P < 0.001), referral to hepatology (OR = 9.60 versus 0.56, P < 0.001) and treatment initiation (OR = 9.5 versus 0.74, P < 0.001). CONCLUSIONS: Introducing a half-time facilitator into drug and alcohol clinics in England increased engagement of HCV-positive people who inject drugs with hepatitis C virus care pathways, with increased uptake also of testing, referral to hepatology and initiation of treatment.
Authors: David Ortiz-Paredes; Afia Amoako; Taline Ekmekjian; Kim Engler; Bertrand Lebouché; Marina B Klein Journal: Front Public Health Date: 2022-06-24
Authors: Stephen P Connolly; Gordana Avramovic; Walter Cullen; Tina McHugh; Eileen O'Connor; Geoff Mc Combe; Des Crowley; Anna Marie Naughton; Aidan Horan; John S Lambert Journal: Ir J Med Sci Date: 2020-08-06 Impact factor: 1.568
Authors: Matthew Hickman; John F Dillon; Lawrie Elliott; Daniela De Angelis; Peter Vickerman; Graham Foster; Peter Donnan; Ann Eriksen; Paul Flowers; David Goldberg; William Hollingworth; Samreen Ijaz; David Liddell; Sema Mandal; Natasha Martin; Lewis J Z Beer; Kate Drysdale; Hannah Fraser; Rachel Glass; Lesley Graham; Rory N Gunson; Emma Hamilton; Helen Harris; Magdalena Harris; Ross Harris; Ellen Heinsbroek; Vivian Hope; Jeremy Horwood; Sarah Karen Inglis; Hamish Innes; Athene Lane; Jade Meadows; Andrew McAuley; Chris Metcalfe; Stephanie Migchelsen; Alex Murray; Gareth Myring; Norah E Palmateer; Anne Presanis; Andrew Radley; Mary Ramsay; Pantelis Samartsidis; Ruth Simmons; Katy Sinka; Gabriele Vojt; Zoe Ward; David Whiteley; Alan Yeung; Sharon J Hutchinson Journal: BMJ Open Date: 2019-09-24 Impact factor: 2.692
Authors: Patricia A M Kracht; Elisabeth A de Gee; Agnes van der Poel; Marc A M T Verhagen; Andy I M Hoepelman; Esther A Croes; Joop E Arends Journal: Harm Reduct J Date: 2019-07-15
Authors: Kirsty Roberts; John Macleod; Chris Metcalfe; Will Hollingworth; Jack Williams; Peter Muir; Peter Vickerman; Clare Clement; Fiona Gordon; Will Irving; Cherry-Ann Waldron; Paul North; Philippa Moore; Ruth Simmons; Alec Miners; Jeremy Horwood; Matthew Hickman Journal: BMJ Date: 2020-02-26
Authors: A Seaman; C A King; T Kaser; A Geduldig; W Ronan; R Cook; B Chan; X A Levander; K C Priest; P T Korthuis Journal: Int J Drug Policy Date: 2021-07-27